High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure
Keiko Maeda, MD, >a,
Takayoshi Tsutamoto, MD, >a,
Atsuyuki Wada, MD, >a,
Naoko Mabuchi, MD, >a,
Masaru Hayashi, MD, >a,
Takashi Tsutsui, MD, >a,
Masato Ohnishi, MD, >a,
Masahide Sawaki, MD, >a,
Masanori Fujii, MD, >a,
Takehiro Matsumoto, MD, >a and
Masahiko Kinoshita, MD, >a
a First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan
View larger version (24K):
[in a new window]
|
Figure 2 Comparison of plasma levels of neurohumoral factors and cytokines before and three months after optimized additional treatment for heart failure in patients with congestive heart failure. *p < 0.0001 vs. before additional treatment for congestive heart failure. ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; NE = norepinephrine; IL-6 = interleukin-6.
|
|
View larger version (31K):
[in a new window]
|
Figure 3 Kaplan-Meier survival (A) and cardiac event-free rate (B) plots for 102 patients with congestive heart failure subdivided into two groups according to the median level of BNP (170 pg/ml) and IL-6 (3.0 pg/ml) three months after additional treatment for congestive heart failure. BNP = brain natriuretic peptide; IL-6 = interleukin-6.
|
|
View larger version (18K):
[in a new window]
|
Figure 4 Plot showing receiver operating characteristic curves for prediction of mortality (A) and morbidity and mortality (B) for plasma level of BNP and IL-6. BNP = brain natriuretic peptide; IL-6 = interleukin-6.
|
|
|
